Eli Lilly and Company (LLY)vsUroGen Pharma Ltd (URGN)
LLY
Eli Lilly and Company
$1,180.16
-2.24%
HEALTHCARE · Cap: $1.02T
URGN
UroGen Pharma Ltd
$48.22
+0.21%
HEALTHCARE · Cap: $1.86B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 51325% more annual revenue ($72.25B vs $140.49M). LLY leads profitability with a 35.0% profit margin vs -94.8%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
URGN
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Revenue surging 151.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 33.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1481.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : URGN
The strongest argument for URGN centers on Revenue Growth, Debt/Equity. Revenue growth of 151.6% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, P/E Ratio, Debt/Equity. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : URGN
The primary concerns for URGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while URGN is a hypergrowth play — different risk/reward profiles.
URGN carries more volatility with a beta of 1.57 — expect wider price swings.
URGN is growing revenue faster at 151.6% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 28/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →UroGen Pharma Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel technology, the company enables targeted, sustained drug delivery, maximizing treatment efficacy while reducing systemic side effects. UroGen's strong clinical pipeline underscores its commitment to addressing substantial unmet medical needs in the oncology space, positioning the company as a potential leader in the urological oncology market and significantly improving patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?